DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
Context:Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs).Objective:The clinical and pathological characteristics of...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 98; no. 3; pp. 1130 - 1136 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bethesda, MD
Oxford University Press
01.03.2013
Copyright by The Endocrine Society Endocrine Society |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-972X 1945-7197 1945-7197 |
| DOI | 10.1210/jc.2012-2924 |
Cover
| Abstract | Context:Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs).Objective:The clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively.Design:Members of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O6-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0.Subjects:Three samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available.Results:The 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows: 4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O6-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisher's exact test).Conclusions:This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses. |
|---|---|
| AbstractList | Context:Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs).Objective:The clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively.Design:Members of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O6-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0.Subjects:Three samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available.Results:The 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows: 4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O6-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisher's exact test).Conclusions:This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses. CONTEXT:Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs). OBJECTIVE:The clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively. DESIGN:Members of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0. SUBJECTS:Three samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available. RESULTS:The 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisherʼs exact test). CONCLUSIONS:This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses. Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs). The clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively. Members of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0. Three samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available. The 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows: 4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisher's exact test). This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses. Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs).CONTEXTTemozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective against atypical pituitary adenomas (APAs) and pituitary carcinomas (PCs).The clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively.OBJECTIVEThe clinical and pathological characteristics of APAs and PCs treated with TMZ in Japan were surveyed and analyzed retrospectively.Members of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0.DESIGNMembers of the Japan Society of Hypothalamic and Pituitary Tumors were surveyed regarding the clinical characteristics of APAs and PCs treated with TMZ. Stored tumor samples were gathered from the responders and were assessed by the immunohistochemistry of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, p53, MSH6, and anterior pituitary hormones. Responses to TMZ treatment were defined as complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) according to RECIST (Response Evaluation Criteria in Solid Tumors) version 2.0.Three samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available.SUBJECTSThree samples from 3 subjects with APA and 11 samples from 10 subjects with PC were available.The 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows: 4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisher's exact test).RESULTSThe 13 subjects had APAs and PCs consisting of 5 prolactin-producing tumors, 5 ACTH-producing tumors, and 3 null cell adenomas. The clinical response to TMZ treatment was as follows: 4 cases of CR and PR (31%), 2 cases of SD (15%), 6 cases of recurrence after CR and PR (46%), and 1 case of PD (8%). However, considerable subjects had recurrent disease after a response to TMZ. The immunohistochemical findings of Ki-67, O(6)-methyl-guanine-DNA methyltransferase, and p53 did not show any significant correlation with the efficacy of TMZ. However, the immunopositivity of MSH6 was positively correlated with TMZ response (P = .015, Fisher's exact test).This study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses.CONCLUSIONSThis study showed that preserving MSH6 function was contributory to the effectiveness of TMZ in malignant pituitary neoplasms. It is necessary to survey more cases and evaluate multifactor analyses. |
| Author | Ikeda, Hidetoshi Isozaki, Osamu Iwai, Yoshiyasu Shimatsu, Akira Hizuka, Naomi Teramoto, Akira Fukuhara, Noriaki Tominaga, Atsushi Hirohata, Toshio Takano, Shingo Yamada, Shozo Osamura, R. Yoshiyuki Arita, Kazunori Matsuno, Akira Tahara, Shigeyuki Ishii, Yudo Amano, Kosaku Sakata, Kiyohiko Nishioka, Hiroshi Takano, Koji Kawamata, Takakazu Ogawa, Yoshikazu Asano, Kenichiro Fujio, Shingo |
| AuthorAffiliation | Departments of Neurosurgery (T.H.) and Nephrology and Endocrinology (K.T.), the University of Tokyo, Tokyo 113-8655, Japan; Department of Neurosurgery (T.H., A.M.), Teikyo University Chiba Medical Center, Ichihara 299-011, Japan; Department of Neurosurgery (K.As.), Hirosaki University Graduate School of Medicine, Hirosaki 036-8203, Japan; Department of Neurosurgery (Y.O.), Konan Hospital, Sendai 982-0012, Japan; Department of Neurosurgery (S.T.), Tsukuba University, Tsukuba 305-0006, Japan; Departments of Neurosurgery (K.Am., T.K.) and Internal Medicine II (O.I., N.H.), Tokyo Womenʼs Medical University, Tokyo 162-8666, Japan; Department of Neurosurgery (Y.Iw.), Osaka City General Hospital, Osaka 534-0021, Japan; Department of Neurosurgery (K.S.), Kurume University School of Medicine, Kurume 830-0011, Japan; Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), |
| AuthorAffiliation_xml | – name: Departments of Neurosurgery (T.H.) and Nephrology and Endocrinology (K.T.), the University of Tokyo, Tokyo 113-8655, Japan; Department of Neurosurgery (T.H., A.M.), Teikyo University Chiba Medical Center, Ichihara 299-011, Japan; Department of Neurosurgery (K.As.), Hirosaki University Graduate School of Medicine, Hirosaki 036-8203, Japan; Department of Neurosurgery (Y.O.), Konan Hospital, Sendai 982-0012, Japan; Department of Neurosurgery (S.T.), Tsukuba University, Tsukuba 305-0006, Japan; Departments of Neurosurgery (K.Am., T.K.) and Internal Medicine II (O.I., N.H.), Tokyo Womenʼs Medical University, Tokyo 162-8666, Japan; Department of Neurosurgery (Y.Iw.), Osaka City General Hospital, Osaka 534-0021, Japan; Department of Neurosurgery (K.S.), Kurume University School of Medicine, Kurume 830-0011, Japan; Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), Toranomon Hospital, Tokyo 105-0001, Japan; Department of Neurosurgery (S.F., K.Ar.), Kagoshima University, Kagoshima 890-0075, Japan; Department of Neurosurgery (A.T.), Hiroshima University, Hiroshima 734-0037, Japan; Department of Neurosurgery (H.I.), Southern Tohoku General Hospital, Koriyama 963-8052, Japan; Department of Pathology (R.Y.O.), International University of Health and Welfare Mita Hospital, Tokyo 108-8329, Japan; Department of Neurosurgery (S.T., Y.Is., A.T.), Nippon Medical School, Tokyo 113-0031, Japan; Department of Neurosurgery (T.K.), Tokyo Womenʼs Medical University Yachiyo Medical Center, Yachiyo 276-0046, Japan; and Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-0861, Japan |
| Author_xml | – sequence: 1 givenname: Toshio surname: Hirohata fullname: Hirohata, Toshio email: hirohata-tky@umin.ac.jp organization: 1Departments of Neurosurgery (T.H.), Tokyo 113-8655, Japan – sequence: 2 givenname: Kenichiro surname: Asano fullname: Asano, Kenichiro organization: 4Department of Neurosurgery (K.As.), Hirosaki University Graduate School of Medicine, Hirosaki 036-8203, Japan – sequence: 3 givenname: Yoshikazu surname: Ogawa fullname: Ogawa, Yoshikazu organization: 5Department of Neurosurgery (Y.O.), Konan Hospital, Sendai 982-0012, Japan – sequence: 4 givenname: Shingo surname: Takano fullname: Takano, Shingo organization: 6Department of Neurosurgery (S.T.), Tsukuba University, Tsukuba 305-0006, Japan – sequence: 5 givenname: Kosaku surname: Amano fullname: Amano, Kosaku organization: 4Department of Neurosurgery (K.As.), Hirosaki University Graduate School of Medicine, Hirosaki 036-8203, Japan – sequence: 6 givenname: Osamu surname: Isozaki fullname: Isozaki, Osamu organization: 8Internal Medicine II (O.I., N.H.), Tokyo Women's Medical University, Tokyo 162-8666, Japan – sequence: 7 givenname: Yoshiyasu surname: Iwai fullname: Iwai, Yoshiyasu organization: 9Department of Neurosurgery (Y.Iw.), Osaka City General Hospital, Osaka 534-0021, Japan – sequence: 8 givenname: Kiyohiko surname: Sakata fullname: Sakata, Kiyohiko organization: 10Department of Neurosurgery (K.S.), Kurume University School of Medicine, Kurume 830-0011, Japan – sequence: 9 givenname: Noriaki surname: Fukuhara fullname: Fukuhara, Noriaki organization: 11Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), Toranomon Hospital, Tokyo 105-0001, Japan – sequence: 10 givenname: Hiroshi surname: Nishioka fullname: Nishioka, Hiroshi organization: 11Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), Toranomon Hospital, Tokyo 105-0001, Japan – sequence: 11 givenname: Shozo surname: Yamada fullname: Yamada, Shozo organization: 11Department of Hypothalamic and Pituitary Surgery (N.F., H.N., S.Y.), Toranomon Hospital, Tokyo 105-0001, Japan – sequence: 12 givenname: Shingo surname: Fujio fullname: Fujio, Shingo organization: 13Department of Neurosurgery (S.F., K.Ar.), Kagoshima University, Kagoshima 890-0075, Japan – sequence: 13 givenname: Kazunori surname: Arita fullname: Arita, Kazunori organization: 13Department of Neurosurgery (S.F., K.Ar.), Kagoshima University, Kagoshima 890-0075, Japan – sequence: 14 givenname: Koji surname: Takano fullname: Takano, Koji organization: 2Nephrology and Endocrinology (K.T.), the University of Tokyo, Tokyo 113-8655, Japan – sequence: 15 givenname: Atsushi surname: Tominaga fullname: Tominaga, Atsushi organization: 14Department of Neurosurgery (A.T.), Hiroshima University, Hiroshima 734-0037, Japan – sequence: 16 givenname: Naomi surname: Hizuka fullname: Hizuka, Naomi organization: 8Internal Medicine II (O.I., N.H.), Tokyo Women's Medical University, Tokyo 162-8666, Japan – sequence: 17 givenname: Hidetoshi surname: Ikeda fullname: Ikeda, Hidetoshi organization: 15Department of Neurosurgery (H.I.), Southern Tohoku General Hospital, Koriyama 963-8052, Japan – sequence: 18 givenname: R. Yoshiyuki surname: Osamura fullname: Osamura, R. Yoshiyuki organization: 16Department of Pathology (R.Y.O.), International University of Health and Welfare Mita Hospital, Tokyo 108-8329, Japan – sequence: 19 givenname: Shigeyuki surname: Tahara fullname: Tahara, Shigeyuki organization: 6Department of Neurosurgery (S.T.), Tsukuba University, Tsukuba 305-0006, Japan – sequence: 20 givenname: Yudo surname: Ishii fullname: Ishii, Yudo organization: 17Department of Neurosurgery (S.T., Y.Is., A.T.), Nippon Medical School, Tokyo 113-0031, Japan – sequence: 21 givenname: Takakazu surname: Kawamata fullname: Kawamata, Takakazu organization: 7Departments of Neurosurgery (K.Am., T.K.), Tokyo 162-8666, Japan – sequence: 22 givenname: Akira surname: Shimatsu fullname: Shimatsu, Akira organization: 19Clinical Research Institute (A.S.), National Hospital Organization Kyoto Medical Center, Kyoto 612-0861, Japan – sequence: 23 givenname: Akira surname: Teramoto fullname: Teramoto, Akira organization: 14Department of Neurosurgery (A.T.), Hiroshima University, Hiroshima 734-0037, Japan – sequence: 24 givenname: Akira surname: Matsuno fullname: Matsuno, Akira organization: 3Department of Neurosurgery (T.H., A.M.), Teikyo University Chiba Medical Center, Ichihara 299-011, Japan |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27109554$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23365123$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFk11rFDEUhgep2G31zmsJiFjBqckk87HeLevHKm0t7oLehTOZM2y2M5MxyVjWv-sfMftRlIViSAiZed73hHNOTqKjznQYRU8ZPWcJo29W6jyhLImTcSIeRCM2Fmmcs3F-FI0oTVg8zpPvx9GJcytKmRApfxQdJ5xnKUv4KPr97mpCLrVrwasl-Yo9aEuurfGoO3J2OZ9lr8jUWIsNeKzIN-2XxC8xkK43nUNHTE0mft1rBQ251n7QHuyaTCrsTAuOQFf983kKVundD2_IAlvzyzSm1RW-JYtgewVemy44TY3p0YbTTyRzP1RrUq63gT9DDx2ZG6XRr0ltLJmte-OX0ECr1UG4xdAa6x5HD2toHD7Z76fR4sP7xXQWX3z5-Gk6uYiVSMdFDKrIFeUIqmSKqwKBQV1UKEStOA2TU1qWpagzBqKoUkFrmgssEwBaMOSn0dnOtrfmx4DOy1Y7hU0DHZrBSZamLBMsFOH_KGdpxvMspwF9foCuzGBDipzkwU5kabqlnu2poWyxkr3VbUiAvCt0AF7sAXChUrWFTmn3l8sZHafp5mbJjlPWOGexliqkclMUb0E3klG56Tq5UnLTdXLTdUH0-kB053sPLnb4rWk8WnfTDLdo5RKh8UtJwxBZXsRBsM05jcPiRZC93MnM0N8XYPsK-B85P_YQ |
| CODEN | JCEMAZ |
| CitedBy_id | crossref_primary_10_1055_a_1331_6939 crossref_primary_10_1007_s11102_017_0855_1 crossref_primary_10_1007_s11102_018_0872_8 crossref_primary_10_1002_ccr3_39 crossref_primary_10_1530_EJE_17_0796 crossref_primary_10_1007_s00701_021_04953_6 crossref_primary_10_1016_j_beem_2022_101713 crossref_primary_10_1007_s12020_015_0685_8 crossref_primary_10_1227_neu_0000000000002024 crossref_primary_10_1007_s40619_014_0092_z crossref_primary_10_1586_17446651_2016_1153422 crossref_primary_10_1007_s11102_020_01040_4 crossref_primary_10_1007_s12022_017_9474_7 crossref_primary_10_1080_17446651_2020_1802243 crossref_primary_10_1177_1179551420932921 crossref_primary_10_1210_clinem_dgad098 crossref_primary_10_2217_frd_2021_0007 crossref_primary_10_1007_s42000_018_0070_0 crossref_primary_10_1007_s42000_019_00145_1 crossref_primary_10_1038_s41574_021_00550_w crossref_primary_10_3390_cancers15020496 crossref_primary_10_1007_s11102_016_0745_y crossref_primary_10_1007_s11060_015_1991_y crossref_primary_10_1111_his_14271 crossref_primary_10_17650_1683_3295_2024_26_4_54_64 crossref_primary_10_1097_PCR_0000000000000180 crossref_primary_10_2174_0113816128290025240216110928 crossref_primary_10_1111_cen_15065 crossref_primary_10_1007_s11102_023_01341_4 crossref_primary_10_1007_s11102_019_01000_7 crossref_primary_10_1007_s11102_015_0694_x crossref_primary_10_1007_s11102_023_01320_9 crossref_primary_10_1007_s12022_019_9568_5 crossref_primary_10_3389_fendo_2021_616339 crossref_primary_10_3389_fendo_2018_00318 crossref_primary_10_1159_000371806 crossref_primary_10_1007_s11102_017_0829_3 crossref_primary_10_1007_s11060_017_2740_1 crossref_primary_10_1016_j_endien_2020_08_011 crossref_primary_10_1210_jc_2017_02332 crossref_primary_10_1016_j_eprac_2024_10_008 crossref_primary_10_1371_journal_pone_0089750 crossref_primary_10_1016_j_patol_2020_11_006 crossref_primary_10_1210_jc_2017_01401 crossref_primary_10_17116_patol20198101171 crossref_primary_10_3390_jcm8111951 crossref_primary_10_1007_s42000_020_00269_9 crossref_primary_10_1507_endocrj_EJ23_0007 crossref_primary_10_1007_s11154_020_09562_9 crossref_primary_10_1016_j_wneu_2018_07_082 crossref_primary_10_1507_endocrj_EJ17_0036 crossref_primary_10_3389_fendo_2024_1440247 crossref_primary_10_1016_j_endinu_2019_08_004 crossref_primary_10_1007_s00795_013_0050_z crossref_primary_10_1007_s11102_017_0857_z crossref_primary_10_1530_EJE_13_1031 crossref_primary_10_1530_EJE_17_0216 crossref_primary_10_1530_EJE_17_0933 crossref_primary_10_1517_14656566_2013_806488 crossref_primary_10_18632_oncotarget_14936 crossref_primary_10_1007_s42000_021_00333_y crossref_primary_10_1155_2015_587893 crossref_primary_10_1007_s11154_020_09551_y crossref_primary_10_1210_jendso_bvab190 crossref_primary_10_1097_MD_0000000000005268 crossref_primary_10_2176_nmc_ra_2014_0178 crossref_primary_10_1007_s11102_018_0865_7 crossref_primary_10_3389_fendo_2023_1204206 crossref_primary_10_1097_MD_0000000000008733 crossref_primary_10_1530_EJE_16_0979 crossref_primary_10_1016_j_endinu_2020_10_004 crossref_primary_10_1016_j_ijscr_2023_108376 crossref_primary_10_36401_JIPO_22_25 crossref_primary_10_1530_ERC_18_0015 crossref_primary_10_1007_s11102_018_0862_x crossref_primary_10_1007_s12022_018_9521_z crossref_primary_10_1007_s11102_021_01192_x crossref_primary_10_1016_j_lpm_2016_05_008 crossref_primary_10_1016_j_endien_2020_10_007 crossref_primary_10_1111_cen_12727 crossref_primary_10_1007_s40278_013_3550_7 crossref_primary_10_1507_endocrj_EJ20230711 crossref_primary_10_3389_fendo_2021_624686 crossref_primary_10_3389_fneur_2021_700007 crossref_primary_10_3389_fendo_2021_650791 crossref_primary_10_1016_j_wneu_2016_09_092 crossref_primary_10_1002_jcp_27759 |
| Cites_doi | 10.14310/horm.2002.1307 10.1002/cncr.25413 10.1007/s11102-009-0211-1 10.1210/jc.2004-2231 10.1158/1078-0432.CCR-06-2149 10.1101/cshperspect.a001016 10.1210/jcem.83.12.5300 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3 10.1158/1078-0432.CCR-10-0821 10.1097/00006123-199601000-00024 10.1530/EJE-10-0629 10.1210/jc.2010-0441 10.1210/jc.2010-0644 10.1007/s11102-011-0341-0 10.1007/s00401-007-0279-5 10.3171/2009.7.JNS09285 10.1111/j.1365-2265.2008.03487.x 10.1158/1078-0432.CCR-06-2053 10.1227/NEU.0b013e318217161a 10.1093/annonc/mdl056 10.1055/s-0030-1253419 10.1111/j.1471-4159.2005.03583.x 10.1007/s12022-007-9006-y 10.1158/1078-0432.CCR-08-3012 10.3171/jns.1986.65.6.0733 10.1016/j.ccr.2006.05.013 10.1056/NEJMoa043331 10.1200/JCO.2002.20.5.1375 10.1007/s00280-002-0473-z 10.1007/s11060-011-0532-6 10.1158/0008-5472.CAN-06-0127 |
| ContentType | Journal Article |
| Copyright | Copyright © 2013 by The Endocrine Society 2013 Copyright © 2013 by The Endocrine Society 2014 INIST-CNRS |
| Copyright_xml | – notice: Copyright © 2013 by The Endocrine Society 2013 – notice: Copyright © 2013 by The Endocrine Society – notice: 2014 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
| DOI | 10.1210/jc.2012-2924 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts Nucleic Acids Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | 1136 |
| ExternalDocumentID | 23365123 27109554 10_1210_jc_2012_2924 00004678-201303000-00038 10.1210/jc.2012-2924 |
| Genre | Journal Article |
| GeographicLocations | Asia Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AERZD AFFNX AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV N4W NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION IQODW PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM AEHZK H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c4598-ac87c03eacb1c3c8ea1af8de44fc30c30300bbb4f61a48d540f074eb2aa081e3 |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Sat Sep 27 18:33:37 EDT 2025 Sat Sep 27 18:24:06 EDT 2025 Fri Sep 19 20:56:52 EDT 2025 Thu Apr 03 07:03:49 EDT 2025 Mon Jul 21 09:16:48 EDT 2025 Tue Jul 01 00:49:59 EDT 2025 Thu Apr 24 23:02:14 EDT 2025 Fri May 16 04:03:21 EDT 2025 Fri Feb 07 10:35:44 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Endocrinopathy Antineoplastic agent Obesity Endocrine gland Carcinoma Nutrition Nutrition disorder Metabolic diseases Malignant tumor Protein Alkylating agent DNA Pituitary diseases Pituitary adenoma Pituitary gland Atypical Society Temozolomide Repair Endocrinology Nutritional status Cancer |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c4598-ac87c03eacb1c3c8ea1af8de44fc30c30300bbb4f61a48d540f074eb2aa081e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 23365123 |
| PQID | 3164465570 |
| PQPubID | 2046206 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1551641014 proquest_miscellaneous_1315637670 proquest_journals_3164465570 pubmed_primary_23365123 pascalfrancis_primary_27109554 crossref_citationtrail_10_1210_jc_2012_2924 crossref_primary_10_1210_jc_2012_2924 wolterskluwer_health_00004678-201303000-00038 oup_primary_10_1210_jc_2012-2924 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-March |
| PublicationDateYYYYMMDD | 2013-03-01 |
| PublicationDate_xml | – month: 03 year: 2013 text: 2013-March |
| PublicationDecade | 2010 |
| PublicationPlace | Bethesda, MD |
| PublicationPlace_xml | – name: Bethesda, MD – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2013 |
| Publisher | Oxford University Press Copyright by The Endocrine Society Endocrine Society |
| Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society – name: Endocrine Society |
| References | Hermisson ( key 2019041114055777100_B5) 2006; 96 Cahill ( key 2019041114055777100_B12) 2007; 13 Park ( key 2019041114055777100_B15) 2002; 50 Kaltsas ( key 2019041114055777100_B3) 2005; 90 Robles ( key 2019041114055777100_B23) 2010; 2 Bode ( key 2019041114055777100_B33) 2010; 118 Trudeau ( key 2019041114055777100_B16) 2006; 17 Scheithauer ( key 2019041114055777100_B4) 1986; 65 Syro ( key 2019041114055777100_B9) 2011; 117 Ekeblad ( key 2019041114055777100_B7) 2007; 13 Pernicone ( key 2019041114055777100_B18) 1997; 79 DeLellis ( key 2019041114055777100_B1) 2004 Losa ( key 2019041114055777100_B13) 2010; 163 Moshkin ( key 2019041114055777100_B31) 2011; 10 Stupp ( key 2019041114055777100_B6) 2002; 20 Thapar ( key 2019041114055777100_B2) 1996; 38 Kovacs ( key 2019041114055777100_B20) 2008; 115 Tanizaki ( key 2019041114055777100_B25) 2007; 18 McCormack ( key 2019041114055777100_B21) 2009; 71 Thearle ( key 2019041114055777100_B34) 2011; 14 Raverot ( key 2019041114055777100_B8) 2010; 95 Hegi ( key 2019041114055777100_B10) 2005; 352 Hunter ( key 2019041114055777100_B11) 2006; 66 Yip ( key 2019041114055777100_B28) 2009; 15 Bush ( key 2019041114055777100_B14) 2010; 95 Kaltsas ( key 2019041114055777100_B17) 1998; 83 Martin ( key 2019041114055777100_B26) 2010; 16 Bocangel ( key 2019041114055777100_B24) 2009; 29 Murakami ( key 2019041114055777100_B29) 2011; 68 Scheithauer ( key 2019041114055777100_B19) 2005; 56 Salehi ( key 2019041114055777100_B22) 2011; 104 Ikeda ( key 2019041114055777100_B30) 2010; 112 Jouanneau ( key 2019041114055777100_B32) 2012; 15 Wang ( key 2019041114055777100_B27) 2006; 9 |
| References_xml | – volume: 10 start-page: 162 issue: 2 year: 2011 ident: key 2019041114055777100_B31 article-title: Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy publication-title: Hormones doi: 10.14310/horm.2002.1307 – volume: 117 start-page: 454 year: 2011 ident: key 2019041114055777100_B9 article-title: Treatment of pituitary neoplasms with temozolomide publication-title: Cancer doi: 10.1002/cncr.25413 – volume: 14 start-page: 418 issue: 4 year: 2011 ident: key 2019041114055777100_B34 article-title: Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor publication-title: Pituitary doi: 10.1007/s11102-009-0211-1 – volume: 90 start-page: 3089 year: 2005 ident: key 2019041114055777100_B3 article-title: Diagnosis and management of pituitary carcinomas publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2004-2231 – volume: 13 start-page: 2038 issue: 7 year: 2007 ident: key 2019041114055777100_B12 article-title: Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmen publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2149 – volume: 2 start-page: a001016 year: 2010 ident: key 2019041114055777100_B23 article-title: Clinical outcomes and correlates of TP53 mutations and cancer publication-title: Cold Spring Harbor Perspect Biol doi: 10.1101/cshperspect.a001016 – volume: 83 start-page: 4233 year: 1998 ident: key 2019041114055777100_B17 article-title: The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.83.12.5300 – volume: 56 start-page: 1066 year: 2005 ident: key 2019041114055777100_B19 article-title: Pituitary carcinoma: a clinicopathological review publication-title: Neurosurgery – volume: 79 start-page: 804 year: 1997 ident: key 2019041114055777100_B18 article-title: Pituitary carcinoma: a clinicopathologic study of 15 cases publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3 – volume: 16 start-page: 5107 issue: 21 year: 2010 ident: key 2019041114055777100_B26 article-title: A therapeutic targeting of the DNA mismatch repair pathway publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-0821 – volume: 38 start-page: 9 year: 1996 ident: key 2019041114055777100_B2 article-title: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody publication-title: Neurosurgery doi: 10.1097/00006123-199601000-00024 – volume: 163 start-page: 843 year: 2010 ident: key 2019041114055777100_B13 article-title: Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases publication-title: Eur J Endocrinol doi: 10.1530/EJE-10-0629 – volume: 95 start-page: E280 year: 2010 ident: key 2019041114055777100_B14 article-title: Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-0441 – volume: 29 start-page: 3741 issue: 10 year: 2009 ident: key 2019041114055777100_B24 article-title: p53-mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor publication-title: Anticancer Res – volume: 95 start-page: 4592 issue: 10 year: 2010 ident: key 2019041114055777100_B8 article-title: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2010-0644 – volume: 15 start-page: 37 issue: 1 year: 2012 ident: key 2019041114055777100_B32 article-title: New targeted therapies in pituitary carcinoma resistant to temozolomide publication-title: Pituitary doi: 10.1007/s11102-011-0341-0 – volume: 115 start-page: 261 year: 2008 ident: key 2019041114055777100_B20 article-title: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy publication-title: Acta Neuropathol doi: 10.1007/s00401-007-0279-5 – volume: 112 start-page: 750 year: 2010 ident: key 2019041114055777100_B30 article-title: Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma publication-title: J Neurosurg doi: 10.3171/2009.7.JNS09285 – volume: 71 start-page: 226 year: 2009 ident: key 2019041114055777100_B21 article-title: Low O6-methylguanine-DNA-methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2008.03487.x – volume: 13 start-page: 2986 year: 2007 ident: key 2019041114055777100_B7 article-title: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2053 – volume: 68 start-page: E1761 year: 2011 ident: key 2019041114055777100_B29 article-title: A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report publication-title: Neurosurgery doi: 10.1227/NEU.0b013e318217161a – volume: 17 start-page: 952 issue: 6 year: 2006 ident: key 2019041114055777100_B16 article-title: Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada-Clinical Trials Group (NCIC-CTG) publication-title: Ann Oncol doi: 10.1093/annonc/mdl056 – volume: 118 start-page: 760 year: 2010 ident: key 2019041114055777100_B33 article-title: SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases publication-title: Exp Clin Endocrinol Diabetes doi: 10.1055/s-0030-1253419 – volume: 96 start-page: 766 issue: 3 year: 2006 ident: key 2019041114055777100_B5 article-title: O6-Methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells publication-title: J Neurochem doi: 10.1111/j.1471-4159.2005.03583.x – volume-title: WHO Classification of Tumors, Pathology and Genetics: Tumors of Endocrine Organs year: 2004 ident: key 2019041114055777100_B1 – volume: 18 start-page: 217 year: 2007 ident: key 2019041114055777100_B25 article-title: p53 gene mutations in pituitary carcinomas publication-title: Endocr Pathol doi: 10.1007/s12022-007-9006-y – volume: 15 start-page: 4622 year: 2009 ident: key 2019041114055777100_B28 article-title: MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-3012 – volume: 65 start-page: 733 year: 1986 ident: key 2019041114055777100_B4 article-title: Pathology of invasive pituitary tumors with special references of functional classification publication-title: J Neurosurg doi: 10.3171/jns.1986.65.6.0733 – volume: 9 start-page: 417 year: 2006 ident: key 2019041114055777100_B27 article-title: Mismatch repair proteins as sensors of alkylation DNA damage publication-title: Cancer Cell doi: 10.1016/j.ccr.2006.05.013 – volume: 352 start-page: 997 year: 2005 ident: key 2019041114055777100_B10 article-title: MGMT gene silencing and benefit from temozolomide in glioblastoma publication-title: N Engl J Med doi: 10.1056/NEJMoa043331 – volume: 20 start-page: 1375 issue: 5 year: 2002 ident: key 2019041114055777100_B6 article-title: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.5.1375 – volume: 50 start-page: 160 issue: 2 year: 2002 ident: key 2019041114055777100_B15 article-title: A phase II trial of oral temozolomide in patients with metastatic renal cell cancer publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-002-0473-z – volume: 104 start-page: 647 year: 2011 ident: key 2019041114055777100_B22 article-title: MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas publication-title: J Neurooncol doi: 10.1007/s11060-011-0532-6 – volume: 66 start-page: 3987 issue: 8 year: 2006 ident: key 2019041114055777100_B11 article-title: A hypermutation phenotype and somatic MSH6 mutations in human malignant gliomas after alkylataorchemotherapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-0127 |
| SSID | ssj0014453 |
| Score | 2.4220953 |
| Snippet | Context:Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be... CONTEXT:Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be... Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic agent for malignant gliomas. Recently, TMZ has been documented to be effective... |
| SourceID | proquest pubmed pascalfrancis crossref wolterskluwer oup |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1130 |
| SubjectTerms | Adenoma Adenoma - drug therapy Adenoma - metabolism Adenoma - pathology Adrenocorticotropic hormone Adult Aged Antineoplastic Agents, Alkylating - therapeutic use Biological and medical sciences Brain tumors Carcinoma Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Data Collection DNA methyltransferase DNA Modification Methylases - metabolism DNA repair DNA Repair Enzymes - metabolism DNA-Binding Proteins - metabolism Drug Resistance, Neoplasm - physiology Endocrinopathies Feeding. Feeding behavior Female Fundamental and applied biological sciences. Psychology Humans Hypothalamus Hypothalamus. Hypophysis. Epiphysis (diseases) Immunohistochemistry Japan Ki-67 Antigen - metabolism Male Medical sciences Middle Aged Mismatch repair MSH6 protein Non tumoral diseases. Target tissue resistance. Benign neoplasms Null cells p53 Protein Pituitary (anterior) Pituitary hormones Pituitary Neoplasms - drug therapy Pituitary Neoplasms - metabolism Pituitary Neoplasms - pathology Prolactin Retrospective Studies Solid tumors Temozolomide Tumor Suppressor Protein p53 - metabolism Tumor Suppressor Proteins - metabolism Tumors Vertebrates: anatomy and physiology, studies on body, several organs or systems Vertebrates: endocrinology Young Adult |
| Title | DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201303000-00038 https://www.ncbi.nlm.nih.gov/pubmed/23365123 https://www.proquest.com/docview/3164465570 https://www.proquest.com/docview/1315637670 https://www.proquest.com/docview/1551641014 |
| Volume | 98 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3_a9NAFMCPbYIIIn63OscJCsqIJLk0Sf2t1I2qaxWW4fwpXNKL7brmypIytn_Xf8T37i5fKptMoZQ2vTSl75O79969L4S8Tp3Mz0AtsFxudy3P87gVTgSz_CBxMzgpCFP0Q47G_vDI-3zcPd7Y3GhFLa3K5H16eWVeyf9IFY6BXDFL9h8kW38pHIDXIF94BgnD841k_HHc3x3NClA60ymq0nx2hpH_2MASNcfR4dBHq3-AHThOOeqW35XbdYrNGlRsrC452y8vlkpY32blalZiIF0f5iMMHdLZBPXhAbYe0h9gzxixkJcwey5mE1GFb4wr7-JAyqUwdcUPVelq1HQxEw3W53wtXHR4sQRgOMBpqsc2F4xWC2k2nE4asFv1LurUTpFPJEyBeVNUaiFKQPy0KpKoHOxncsq1whzJYqqD0BTwBVdNyDFRaZZOYVztfv7Jz9UJP_CEOb9cNd6OuTnpEP14su1BwW4WVQhZndHgWL1AtXWvV4Ve2KKftaZ4xzEbSaJ661-5FIEtjUsRlsl0XMvt6VTx9Yrf46_x_tHBQRztHUeb5JYbgP6Hiv2nL_VOmOeZSqrmN5rkDcy8an_3mlqlUzXvLnkBf3-mG7RcZUHBmHOJQRnFXOVktDSr6D65Z0wi2td8PyAbIn9Ibo9M0Mcj8gswpxXmVGNODeb0LUL-jjaIU0ScAme0RpzKjFaI0xotWiFOgZXW4QZxWkraRvwDBfZoBThtAU4V4DS5UBdWgFMDOAXAaRvwPy6nAX9Mov29aDC0TG8SK_W6vdDiaRikNgO1JXFSloaCOzyDWc7zspTZ8GC2nSSJl_kO98IJ2EUZKOsicTkHJVywJ2Qrl7l4RmjYs3lXuIGXYLCpm3HHyUCLd1k3wTz3oEN2K8nGqanbj-1jTmO034GD-CSNkYMYOeiQN_Xopa5Xc804CpBcN8TSQ3bWCKoHuxi_DWZIh2xXSMXmvi9i5viqJmNgd8ir-mNYs3AjkudCrorYYU7XxzJSfxuDO_gedhLvkKca1-YHMOaDocI6xFrjN9a547FyfIAWbuHdjpJQxTNY-PwGV3tB7jRzxDbZKs9W4iXYHWWyo27M386WNLk |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=DNA+Mismatch+Repair+Protein+%28MSH6%29+Correlated+With+the+Responses+of+Atypical+Pituitary+Adenomas+and+Pituitary+Carcinomas+to+Temozolomide%3A+The+National+Cooperative+Study+by+the+Japan+Society+for+Hypothalamic+and+Pituitary+Tumors&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Hirohata%2C+Toshio&rft.au=Asano%2C+Kenichiro&rft.au=Ogawa%2C+Yoshikazu&rft.au=Takano%2C+Shingo&rft.date=2013-03-01&rft.issn=0021-972X&rft.volume=98&rft.issue=3&rft.spage=1130&rft.epage=1136&rft_id=info:doi/10.1210%2Fjc.2012-2924&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |